XML 35 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 1 - Significant Accounting Policies (Details Textual)
$ / shares in Units, shares in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
$ / shares
shares
Mar. 31, 2016
USD ($)
Jun. 30, 2015
USD ($)
$ / shares
Jun. 30, 2016
USD ($)
$ / shares
shares
Jun. 30, 2015
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
Mar. 09, 2011
USD ($)
Currency Hedge Agreement [Member]                
Collateral Already Posted, Aggregate Fair Value   $ 1,610,000     $ 1,610,000   $ 0  
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]                
Deferred Revenue, Additions $ 3,740,000              
Derivative, Loss on Derivative         6,441,000 $ 332,000    
Derivative, Gain on Derivative         $ 811,000 1,545,000    
Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | RAPIVAB [Member] | Three Customers [Member]                
Concentration Risk, Percentage         90.00%      
Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | RAPIVAB [Member]                
Number of Major Customers         3      
RAPIVAB [Member] | Agreement [Member] | CSL [Member] | Contingent upon EU Marketing Approval [Member]                
Proceeds from License Fees Received 7,000,000              
RAPIVAB [Member] | Agreement [Member] | CSL [Member] | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]                
Deferred Revenue, Additions 1,223,000              
RAPIVAB [Member] | Agreement [Member] | CSL [Member]                
Proceeds from License Fees Received 33,740,000              
Revenues 21,777,000              
Milestone Payment Maximum $ 12,000,000              
JPR Royalty Sub LLC [Member]                
Revenue Recognition Royalty and Milestone Revenue Recognized               $ 30,000,000
Debt Issuance Costs Reclassifed from Other Current Assets [Member] | December 31, 2015 [Member]                
Prior Period Reclassification Adjustment     $ 2,196,000          
Royalty Receivable [Member]                
Restricted Cash and Cash Equivalents, Current   3,022,000     $ 3,022,000      
Collateral for Credit [Member]                
Restricted Cash and Cash Equivalents, Current   1,404,000     $ 1,404,000      
Maximum [Member]                
Maturity Period of High Quality Marketable Securities         3 years      
Average Maturity Period of High Quality Marketable Securities         1 year 180 days      
Maturity Period of Short Term Investment         1 year      
Average Maturity for Portfolio Investments         1 year 180 days      
Minimum [Member]                
Maturity Period of Short Term Investment         90 days      
Long-term Investment Maturity, Minimum         1 year      
Computer Equipment [Member]                
Property, Plant and Equipment, Useful Life         3 years      
Laboratory Equipment, Office Equipment and Software [Member]                
Property, Plant and Equipment, Useful Life         5 years      
Furniture and Fixtures [Member]                
Property, Plant and Equipment, Useful Life         7 years      
Leasehold Improvements [Member] | Birmingham Research Facility [Member]                
Property, Plant and Equipment, Useful Life         20 years 182 days      
Property, Plant and Equipment, Gross   1,589,000     $ 1,589,000      
Lease Financing Obligation, Net of Current   2,589,000     2,589,000      
PhaRMA Notes Member]                
Interest Expense   1,338,000   $ 1,306,000 2,677,000 2,621,000    
Birmingham Research Facility [Member]                
Interest Expense   83     214,000      
Capital Leases, Future Minimum Payments Due   4,839,000     4,839,000      
Loss on Sale of Investments         0      
Amortization of Debt Issuance Costs   110,000   110,000 220,000 220,000    
Investments and Cash   64,320,000     64,320,000      
Maturity of Investments     3 years          
Restricted Cash and Cash Equivalents, Current   4,426,000     4,426,000   1,612,000  
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax         10,000 12,000    
Revenues   4,787,000   25,842,000 9,607,000 32,668,000    
Interest Expense   1,421,000   $ 1,306,000 2,891,000 $ 2,621,000    
Lease Financing Obligation, Net of Current   $ 2,589,000     $ 2,589,000   $ 2,375,000  
Earnings Per Share, Diluted | $ / shares   $ (0.22)   $ 0.06 $ (0.53) $ (0.14)    
Earnings Per Share, Basic | $ / shares   $ (0.22)   $ 0.07 $ (0.53) $ (0.14)    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares   885     1,091 4,038